InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Callos Andrew | EVP, Chief Commercial Officer | Sale | 15.0K | $63.26 | $949K | 58.6K | View ↗ | |
| 2026-04-15 | Callos Andrew | EVP, Chief Commercial Officer | Sale | 7,449 | $66.02 | $492K | 58.6K | View ↗ | |
| 2026-03-31 | Callos Andrew | EVP, Chief Commercial Officer | Sale | 3,639 | $65.00 | $237K | 66.0K | View ↗ | |
| 2026-03-18 | Callos Andrew | EVP, Chief Commercial Officer | Sale | 1,930 | $62.07 | $120K | 78.2K | View ↗ | |
| 2026-03-17 | Callos Andrew | EVP, Chief Commercial Officer | Sale | 8,542 | $62.15 | $531K | 71.6K | View ↗ |
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-10-09 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-06-17 | Lisa McClain(R-MI09) | house | Sale | $1,001 - $15,000 |
| 2025-06-11 | Lisa McClain(R-MI09) | house | Purchase | $1,001 - $15,000 |
No annual data found.
Why The Cytokinetics (CYTK) Story Is Shifting After Myqorzo Approvals And ACACIA Expectations
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
Cytokinetics: Strong Story, But Valuation Leaves Limited Upside
Cytokinetics to Announce First Quarter Results on May 5, 2026